TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26303750

Group type: EXPERIMENTAL
Intervention: Remifentanil analgesia
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (no analgesia)
Number of subjects: 140
Study: 23354164

Group type: EXPERIMENTAL
Intervention: US-guided in-plain injection
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: US-guided out-of-plain injection
Number of subjects: 126

Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 126
Study: 21750097

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided approach
Number of subjects: 141

Group type: COMPARATOR
Intervention: Blind approach
Number of subjects: 141
Study: 18286488

Group type: EXPERIMENTAL
Intervention: Chemoradiation without planned neck dissection
Number of subjects: 102
Study: 16096781

Group type: EXPERIMENTAL
Intervention: Short cue-target interval (200 ms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Long cue-target interval (2000 ms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Predictable trial sequence
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Short preparatory intervals
Number of subjects: 15
Study: 12748343

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 36
Study: 11090750

Group type: EXPERIMENTAL
Intervention: Roche AMPLICOR EV test (PCR)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Culture
Number of subjects: 465
Study: 8796234

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 10 cmH2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 20 cmH2O
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inspiratory pressure of 0 cmH2O
Number of subjects: 10
Study: 1518731

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1800 mg/day for 6 days
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 6381018

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 0
Study: 30722001

Group type: EXPERIMENTAL
Intervention: Octreotide (100 μg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (1 mL 0.9% saline)
Number of subjects: 36
Study: 29777632

Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF) plus Connective Tissue Graft (CTG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coronally Advanced Flap (CAF) alone
Number of subjects: 25
Study: 27151345

Group type: EXPERIMENTAL
Intervention: BARC bleeding (grades 2, 3, or 5)
Number of subjects: 12944

Group type: EXPERIMENTAL
Intervention: TIMI minor/major bleeding
Number of subjects: 12944

Group type: EXPERIMENTAL
Intervention: GUSTO moderate/severe bleeding
Number of subjects: 12944

Group type: EXPERIMENTAL
Intervention: CABG-related bleeding (BARC 4)
Number of subjects: 12944

Group type: EXPERIMENTAL
Intervention: BARC (2, 3, or 4) bleeding
Number of subjects: 12944

Group type: EXPERIMENTAL
Intervention: BARC 4 bleeding
Number of subjects: 12944

Group type: EXPERIMENTAL
Intervention: Inclusion of BARC (2, 3, or 4) bleeding in the 1-year mortality model
Number of subjects: 12944
Study: 24885789

Group type: EXPERIMENTAL
Intervention: Ultrasound real-time guidance and examination
Number of subjects: 300

Group type: COMPARATOR
Intervention: Landmark guidance and radiographic examination
Number of subjects: 300
Study: 22280352

Group type: EXPERIMENTAL
Intervention: 25 μg/die of vitamin K (G I)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 12 μg/die of vitamin K (G II)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (G III)
Number of subjects: 53
Study: 20164823

Group type: EXPERIMENTAL
Intervention: Erythropoietin (high-dose); administered based on biomarker levels above 46.3
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 18757324

Group type: COMPARATOR
Intervention: Normal-weight patients (BMI, 21 to 24.9 kg/m(2))
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Class II to III obesity (BMI >or= 35 kg/m(2))
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Weight change during adjuvant therapy
Number of subjects: 1053
Study: 15977316

Group type: COMPARATOR
Intervention: Secretin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo in open label
Number of subjects: 0
Study: 12765749

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saccharin
Number of subjects: 12
Study: 9808821

Group type: EXPERIMENTAL
Intervention: Brief proactive educational intervention over the telephone with two follow-up mailouts, based on NCI 5 A Day for Better Health program.
Number of subjects: 1672
Study: 7612098

Group type: EXPERIMENTAL
Intervention: Leboyer childbirth (cord clamping after 3 minutes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Early cord clamping (less than 10 seconds)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Leboyer childbirth and Early cord clamping
Number of subjects: 30
Study: 2142949

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) - 50 micrograms bolus, then 1 microgram/min infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mannitol - 15% at 100 ml/hr
Number of subjects: 20
Study: 301743

Group type: EXPERIMENTAL
Intervention: Surgical treatment (CABG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 57
Study: 29855281

Group type: EXPERIMENTAL
Intervention: TAO, an internet-based program for AjD composed of seven modules combining CBT and Positive Psychology strategies, with short weekly telephone support.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group, assessed before and after a seven-week waiting period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAO intervention measured using BDI-II and BAI as primary outcome measures.
Number of subjects: 0
Study: 28371189

Group type: EXPERIMENTAL
Intervention: Glucagon stimulation test (GST) with 1 mg i.v. glucagon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT) with a liquid mixed meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Correlation between GST and MMTT C‐peptide levels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MMTT GIP and C‐peptide levels
Number of subjects: 10
Study: 26247145

Group type: EXPERIMENTAL
Intervention: Prefilled, color-coded syringes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional medication administration
Number of subjects: 10
Study: 23911734

Group type: EXPERIMENTAL
Intervention: Endovenous microwave ablation (EMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High ligation and stripping (HLS)
Number of subjects: 0
Study: 21426749

Group type: COMPARATOR
Intervention: Control group (30 individuals without CAD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stable angina pectoris (SA) group (30 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Unstable angina pectoris/non-ST-segment elevation myocardial infarction (UA/NSTEMI) group (30 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ST-segment elevation myocardial infarction (STEMI) group (30 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local levels in UA/NSTEMI group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local levels in STEMI group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Coronary sinus levels in STEMI patients
Number of subjects: 120
Study: 18344730

Group type: EXPERIMENTAL
Intervention: 10 mg/d escitalopram
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 20 mg/d escitalopram
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 17089111

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 2.4 mg/kg body weight
Number of subjects: 17
Study: 14554068

Group type: EXPERIMENTAL
Intervention: Compoconnect (CC) (Heraus Kulzer)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clearfil Repair (CF) (Kuraray)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐purpose adhesive resin (MP) (3M‐ESPE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no surface treatment)
Number of subjects: 8
Study: 11574766

Group type: EXPERIMENTAL
Intervention: Chemotherapy with nitrosoureas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive and palliative care including neurorehabilitation
Number of subjects: 0
Study: 9635475

Group type: EXPERIMENTAL
Intervention: Down's syndrome patients with DAT
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nondemented Down's syndrome patients
Number of subjects: 106

Group type: COMPARATOR
Intervention: Japanese nondemented controls
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Down's syndrome patients with DAT under 50 years
Number of subjects: 106
Study: 7810189

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3047339

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin, cyclophosphamide, methotrexate)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Reduced doses of doxorubicin and cyclophosphamide without methotrexate
Number of subjects: 88

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 88
Study: 1448121

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (800 mg sulfamethoxazole and 160 mg trimethoprim once daily)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Aerosolized pentamidine (300 mg administered every four weeks by jet nebulizer)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 310

Group type: COMPARATOR
Intervention: Aerosolized pentamidine
Number of subjects: 310
Study: 756475

Group type: EXPERIMENTAL
Intervention: Multicomponent positive reinforcement procedure emphasizing moderation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional denial-confrontation therapy emphasizing abstinence
Number of subjects: 0
Study: 31856618

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31825027

Group type: EXPERIMENTAL
Intervention: LLLT+PN
Number of subjects: 90

Group type: COMPARATOR
Intervention: LLLT
Number of subjects: 90

Group type: COMPARATOR
Intervention: PN
Number of subjects: 90
Study: 28283018

Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg/kg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Dexmedetomidine (1 μg/kg)
Number of subjects: 77
Study: 25723884

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus DEX (800 mg/m DEX 30 minutes before epirubicin administration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy alone (placebo 30 minutes before epirubicin administration)
Number of subjects: 80
Study: 25232512

Group type: EXPERIMENTAL
Intervention: RV transdermal patch (RV-TDP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: RV capsules (RV-CP)
Number of subjects: 20
Study: 22605639

Group type: EXPERIMENTAL
Intervention: Regular mammographic screening (active study population)
Number of subjects: 57171

Group type: COMPARATOR
Intervention: Usual care (passive study population)
Number of subjects: 57171
Study: 20004330

Group type: EXPERIMENTAL
Intervention: Everolimus (2 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Everolimus (4 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Everolimus (3 ng/mL or less)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 120
Study: 17225920

Group type: EXPERIMENTAL
Intervention: Citric acid addition (60 mg/portion) in product B
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Phytase treatment in product C
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of citric acid addition, dephytinization, and iron supplementation
Number of subjects: 42
Study: 15455740

Group type: EXPERIMENTAL
Intervention: Topical subgingival application of hyaluronic acid gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 20
Study: 11743622

Group type: EXPERIMENTAL
Intervention: 10 ml 1% pilocarpine solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 ml 2% pilocarpine solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 40
Study: 9845139

Group type: EXPERIMENTAL
Intervention: ASA + Aprotinin
Number of subjects: 119

Group type: COMPARATOR
Intervention: placebo + Aprotinin
Number of subjects: 119

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 119
Study: 7986790

Group type: EXPERIMENTAL
Intervention: Riboflavin (5 mg) on 5 days every week for 1 year
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multivitamin supplement (Protovit) plus FeSO4 (200 mg once weekly) on 5 days every week for 1 year
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (lactose) tablet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Riboflavin and Multivitamin groups (combined)
Number of subjects: 90
Study: 2686429

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus azlocillin (regimen 1)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin (regimen 2)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin followed by oral ciprofloxacin (regimen 3)
Number of subjects: 71
Study: 5774314

Group type: EXPERIMENTAL
Intervention: Combined triple antigen vaccines with aluminium hydroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined triple antigen vaccines without aluminium hydroxide (implied control)
Number of subjects: 0
Study: 31173645

Group type: EXPERIMENTAL
Intervention: quizartinib + ketoconazole
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: quizartinib + fluconazole
Number of subjects: 93

Group type: COMPARATOR
Intervention: quizartinib alone
Number of subjects: 93
Study: 27178843

Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pilates
Number of subjects: 56
Study: 25758448

Group type: EXPERIMENTAL
Intervention: Shared Care Model (SCM)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 97
Study: 23816526

Group type: EXPERIMENTAL
Intervention: docetaxel and prednisone
Number of subjects: 220

Group type: COMPARATOR
Intervention: docetaxel and prednisone ± AT101
Number of subjects: 220
Study: 21316913

Group type: EXPERIMENTAL
Intervention: Stryker Full Navigation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stryker Articular Surface Mounted (ASM) navigation
Number of subjects: 40
Study: 19408465

Group type: EXPERIMENTAL
Intervention: Randomized training program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Blocked perceptual training
Number of subjects: 160

Group type: COMPARATOR
Intervention: Reduced feedback (66%)
Number of subjects: 160
Study: 16781604

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761) 240 mg per day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15046478

Group type: EXPERIMENTAL
Intervention: 4 mg of sustained release doxazosin for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 8 mg of sustained release doxazosin after unsuccessful removal with 4 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 40
Study: 11078981

Group type: EXPERIMENTAL
Intervention: hGH (20 microg/kg per day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: hGH
Number of subjects: 111
Study: 9107583

Group type: EXPERIMENTAL
Intervention: Ureteral stents used during and after SWL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine use of ureteral stents
Number of subjects: 0
Study: 1550080

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion
Number of subjects: 160

Group type: COMPARATOR
Intervention: 5-FU plus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU on days 2 to 6
Number of subjects: 160
Study: 3158277

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg perorally, twice a day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole (160‐800 mg perorally, twice a day)
Number of subjects: 45
Study: 30282103

Group type: EXPERIMENTAL
Intervention: Family history of preeclampsia in one or more female relatives
Number of subjects: 9686

Group type: EXPERIMENTAL
Intervention: Family history of preeclampsia in mother
Number of subjects: 9686

Group type: EXPERIMENTAL
Intervention: Family history of preeclampsia in sister(s)
Number of subjects: 9686

Group type: COMPARATOR
Intervention: No family history of preeclampsia
Number of subjects: 9686
Study: 29370827

Group type: EXPERIMENTAL
Intervention: PRO section appearing last in the survey
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Clinical items appearing last in the survey
Number of subjects: 187

Group type: COMPARATOR
Intervention: Clinical items appearing first in the survey
Number of subjects: 187
Study: 28459708

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg IV daily)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 26107256

Group type: EXPERIMENTAL
Intervention: Ashtanga-based Yoga Therapy (AYT) program for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 21
Study: 23933268

Group type: EXPERIMENTAL
Intervention: Multi-level school-based intervention to prevent secondhand smoke exposure
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 1734
Study: 20568437

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) on Neiguan (PC 6) and Taichong (LR 3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paracervical block anesthesia (BA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both TEAS and BA
Number of subjects: 90
Study: 18806616

Group type: EXPERIMENTAL
Intervention: Added treatment group (doxazosin 1‐4 mg and atenolol when needed)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Added treatment group
Number of subjects: 434
Study: 16879463

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg pre-operatively, followed by gabapentin 2 x 600 mg on the day of operation and gabapentin 3 x 600 mg for the next 5 days, with rofecoxib 50 mg daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo with rofecoxib 50 mg daily
Number of subjects: 49
Study: 12882846

Group type: EXPERIMENTAL
Intervention: Low-glycemic index (GI) diets
Number of subjects: 356

Group type: COMPARATOR
Intervention: High-glycemic index (GI) diets
Number of subjects: 356
Study: 10576173

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8704192

Group type: EXPERIMENTAL
Intervention: G‐CSF 300 microgram/d
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (0 microgram/d)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 51
Study: 1680414

Group type: EXPERIMENTAL
Intervention: Glycerol-containing peritoneal dialysis fluid (G-PDF)
Number of subjects: 8
Study: 6960810

Group type: EXPERIMENTAL
Intervention: Levamisole during remission maintenance therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: No levamisole during remission maintenance therapy (control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Levamisole during chemoimmunotherapy
Number of subjects: 37
Study: 31670542

Group type: EXPERIMENTAL
Intervention: SB fading group
Number of subjects: 84

Group type: COMPARATOR
Intervention: No instructions control group
Number of subjects: 84
Study: 30311742

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control group (nonanxious depression)
Number of subjects: 1008
Study: 28673433

Group type: EXPERIMENTAL
Intervention: Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 46
Study: 25198416

Group type: EXPERIMENTAL
Intervention: Help condition (FGCs reflecting on a time when they helped family)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control condition (FGCs not describing an example)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Continuing-generation college students (CGCs)
Number of subjects: 304
Study: 23360692

Group type: EXPERIMENTAL
Intervention: 20 mg of lutein daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20727555

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg, vitamin B6 40 mg, and cyanocobalamin 2 mg per day for 3 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 19930837

Group type: EXPERIMENTAL
Intervention: Sustained-release paracetamol (acetaminophen) tablet formulation, three times daily dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard paracetamol tablets, four times daily dosing
Number of subjects: 0
Study: 16865063

Group type: EXPERIMENTAL
Intervention: Yoga and meditation program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no yoga)
Number of subjects: 18
Study: 12641522

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (rabeprazole 40 mg daily + amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg, and tinidazole 500 mg twice daily for 5 days)
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Standard 7-day therapy (rabeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1 g twice daily)
Number of subjects: 1049
Study: 10708329

Group type: EXPERIMENTAL
Intervention: Verbal drug cues
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neutral cues
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dual task paradigm (probe stimulus and imagery script)
Number of subjects: 24
Study: 8244130

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 2 litres/minute
Number of subjects: 103

Group type: COMPARATOR
Intervention: Air at 2 litres/minute (Control)
Number of subjects: 103